Jonathan Ownby is an Endocrinology/Metabolic physician affiliated with Atlanta Diabetes Associates. OpenAlex indexes 18 publications with 458 citations (h-index 9).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1800 Howell Mill Rd NW
Suite 450
Atlanta, GA 303182538
Telephone
404-355-4393Provider last certified this registry record 4 Apr 2023.
Industry payments
67 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Corcept TherapeuticsProgram year202545 payments$50,006openpaymentsdata.cms.gov ↗
- Abbott LaboratoriesProgram year202512 payments
- Chiesi USA, Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Musculoskeletal
55.6%RANK Ligand Inhibitor55.4%Denosumab100%Part B, office-administered≥37 patientsNonsteroidal Anti-inflammatory Drug0.2%Diclofenac Sodium100%Part D<11 patientsMetabolism & gastrointestinal
27.5%Insulin Analog7.5%Lantus Solostar17%Tresiba Flextouch U-10014%Humalog Kwikpen U-10013%Novolog9%Toujeo Solostar8%Novolog Flexpen8%Humalog7%Insulin Lispro Kwikpen U-1006%Tresiba Flextouch U-2004%Basaglar Kwikpen U-1003%Fiasp Flextouch3%Insulin Lispro3%Lantus3%Fiasp2%Part D<11 patientsGLP-1 receptor agonist7.3%Ozempic56%Mounjaro27%Trulicity11%Rybelsus6%Part D<11 patients+ 6 more classes in this area
Hormonal (systemic)
6.7%l-Thyroxine5.3%Levothyroxine Sodium72%Synthroid28%Part D≥76 patientsThyroid Hormone Synthesis Inhibitor0.4%Methimazole100%Part D≥12 patients+ 4 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”